Sarepta Therapeutics (SRPT) U.K.-Specific Hold Concerns 'Overblown' - William Blair
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
Go back to Sarepta Therapeutics (SRPT) U.K.-Specific Hold Concerns 'Overblown' - William Blair
February 9, 2018 11:45 AM EST
JPMorgan maintains Overweight on Sarepta Therapeutics (NASDAQ: SRPT).
Analyst Anupam Rama defends the stock after speaking with management and states that any material downside is overdone.
For an analyst ratings summary and ratings history on Sarepta Therapeutics... More
February 9, 2018 9:30 AM EST
Pre-Open Movers
Alliance One Int'l (NYSE: AOI) 30.8% HIGHER; Total sales and other operating revenues increased 5.1% to $477.8 million primarily due to the larger South American crop and a 4.9% increase in average sales prices due to product mi
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) 28.4% LOWER; announced the pricing of an underwritten public offering of 30 million shares of its common stock at a price to the public of $2.00 per share.
MobileIron (NASDAQ: MOBL)... More
February 9, 2018 7:45 AM EST
(Updated - February 9, 2018 7:52 AM EST)
Weakness in Sarepta Therapeutics (NASDAQ: SRPT) Friday morning was tied to a report that its UK study of golodirsen was halted.
A report from... More
